FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells

Cancer Research

Volumn 73, Issue 5, 2013, Pages 1570-1580

  Sahu, Biswajyoti ^a   Laakso, Marko ^a,b   Pihlajamaa, Päivi ^a   Ovaska, Kristian ^a,b   Sinielnikov, Ievgenii ^a   Hautaniemi, Sampsa ^a,b   Jänne, Olli A ^a,c,d  

^a Institute of Biomedicine   (Germany)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA;

ARTICLE; BINDING SITE; CANCER CELL; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP 1F5; CELL STRAIN VCAP; CELL TYPE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; RNA INTERFERENCE;

CASTRATION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; LIGANDS; MALE; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84874918445     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2350     Document Type: Article

References (49)

1. Heinlein CA, Chang C. The roles of androgen receptors and androgenbinding proteins in nongenomic androgen actions. Mol Endocrinol 2002;16:2181-7.
2. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
3. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004;61:332-53.
4. Furr BJ. Casodex: Preclinical studies. Eur Urol 1990;18 Suppl 3:2-9.
5. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
6. McLeod DG. Antiandrogenic drugs. Cancer 1993;71:1046-9.
7. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989;14:103-15.
8. Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004;18:2633-48.
9. Kuil CW, Berrevoets CA, Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J Biol Chem 1995; 270:27569-76.
10. Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, et al. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS ONE 2008;3:e3645.
11. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011;30:2719-33.
12. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 2011;30:3962-76.
13. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007;27:380-92.
14. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009;138:245-56.
15. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17:443-54.
16. Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP, Parker CC. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 2008;101:440-3.
17. Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res 2006;12:6012-7.
18. Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 2007;26:1885-96.
19. Denayer S, Helsen C, Thorrez L, Haelens A, Claessens F. The rules of DNA recognition by the androgen receptor. Mol Endocrinol 2010;24: 898-913.
20. John S, Sabo PJ, Thurman RE, Sung MH, Biddie SC, Johnson TA, et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet 2011;43:264-8.
21. Cleutjens CB, Steketee K, van Eekelen CC, van der Korput JA, Brinkmann AO, Trapman J. Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology 1997;138:5293-300.
22. Widen C, Zilliacus J, Gustafsson JA, Wikstrom AC. Glucocorticoid receptor interaction with 14-3-3 and Raf-1, a proposed mechanism for cross-talk of two signal transduction pathways. J Biol Chem 2000; 275:39296-301.
23. Giresi PG, Kim J, McDaniell RM, Iyer VR, Lieb JD. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Res 2007;17: 877-85.
24. Ovaska K, Laakso M, Haapa-Paananen S, Louhimo R, Chen P, Aittomaki V, et al. Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. Genome Med 2010;2:65.
25. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, et al. Cistrome: An integrative platform for transcriptional regulation studies. Genome Biol 2011;12:R83.
26. Boyle AP, Davis S, Shulha HP, Meltzer P, Margulies EH, Weng Z, et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 2008;132:311-22.
27. John S, Sabo PJ, Johnson TA, Sung MH, BiddieSC, Lightman SL, et al. Interaction of the glucocorticoid receptor with the chromatin landscape. Mol Cell 2008;29:611-24.
28. Biddie SC, John S, Sabo PJ, Thurman RE, Johnson TA, Schiltz RL, et al. Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol Cell 2011;43:145-55.
29. Andreu-Vieyra C, Lai J, Berman BP, Frenkel B, Jia L, Jones PA, et al. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol 2011;31:4648-62.
30. Makkonen H, Kauhanen M, Jaaskelainen T, Palvimo JJ. Androgen receptor amplification is reflected in the transcriptional responses of vertebral-cancer of the prostate cells. Mol Cell Endocrinol 2011;331: 57-65.
31. Tan PY, Chang CW, Chng KR, Wansa KD, Sung WK, Cheung E. Integration of regulatory networks by NKX3-1 promotes androgendependent prostate cancer survival. Mol Cell Biol 2012;32: 399-414.
32. Robinson JL, Macarthur S, Ross-Innes CS, TilleyWD, Neal DE, Mills IG, et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 2011;30: 3019-27.
33. He HH, Meyer CA, Shin H, Bailey ST, Wei G, Wang Q, et al. Nucleosome dynamics define transcriptional enhancers. Nat Genet 2010;42:343-7.
34. Voss TC, Schiltz RL, Sung MH, Yen PM, Stamatoyannopoulos JA, Biddie SC, et al. Dynamic exchange at regulatory elements during chromatin remodeling underlies assisted loading mechanism. Cell 2011;146:544-54.
35. Tomlins SA, Mehra R, Rhodes DR, Cao X,WangL, DhanasekharanSM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51.
36. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009;324:407-10.
37. Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, Carroll JS, Brown M. Unique ERa cistromes control cell type-specific gene regulation. Mol Endocrinol 2008;22:2393-406.
38. Lupien M, Eeckhoute J, MeyerCA, Wang Q, Zhang Y, Li W, et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008;132:958-70.
39. Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 2007;21:1835-46.
40. Chng KR, Chang CW, Tan SK, Yang C, Hong SZ, Sng NY, et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J 2012;31:2810-23.
41. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002;9:601-10.
42. Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev 2005;105:3352-70.
43. Augello MA, Hickey TE, Knudsen KE. FOXA1: Master of steroid receptor function in cancer. EMBO J 2011;30:3885-94.
44. Zaret KS, Carroll JS. Pioneer transcription factors: Establishing competence for gene expression. Genes Dev 2011;25:2227-41.
45. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005;122:33-43.
46. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011;20:119-31.
47. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011;474:390-4.
48. Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, et al. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate 2012;72:157-64.
49. Yemelyanov A, Bhalla P, Yang X, Ugolkov A, Iwadate K, Karseladze A, et al. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: A novel therapeutic modality. Cell Cycle 2012;11:395-406.